Os flu capsule 45mg (Oseltamivir phosphate)

Adult dosage

Influenza A and influenza B virus infections: Begin treatment on the first or second day after the onset of influenza symptoms. This medicine may be taken regardless of food intake, although taking it with food may improve tolerability in some patients. Adults and adolescents 13 years of age and older: The recommended dose is 75 mg of oseltamivir orally twice daily for 5 days. Adults and adolescents 13 years of age and older who have difficulty swallowing capsules should use this medicine as a powder for suspension. Patients with renal impairment: No dose adjustment is required for patients with creatinine clearance ≥ 60 mL/min. For patients with creatinine clearance of 30 ~ 60 mL/min, a reduced dose of 30 mg twice daily for 5 days is recommended. For patients with creatinine clearance of 10 ~ 30 mL/min, a reduced dose of 30 mg once daily for 5 days is recommended. Patients receiving regular hemodialysis should receive a 30 mg dose of this medicine after each dialysis session to maintain blood concentrations within the therapeutic range, and treatment should not exceed 5 days. If influenza symptoms develop during the 48 hours between dialysis sessions, the dose may be administered before the start of dialysis. For peritoneal dialysis, a single 30 mg dose of this medicine after dialysis is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min), so no recommended dose is available for these patients. Patients with hepatic impairment: No dose adjustment is required for treatment in adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9). Prevention of influenza A and influenza B virus infections Adults and adolescents 13 years of age and older: For close contacts of an infected person, administer 75 mg of oseltamivir orally once daily for 10 days. Start administration within 2 days of contact with the infected person. The recommended dose for prevention during an influenza outbreak is 75 mg once daily. The safety and efficacy of this medicine have been demonstrated for up to 6 weeks. The preventive effect continues while this medicine is being taken. Patients with renal impairment: No dose adjustment is required for patients with creatinine clearance ≥ 60 mL/min. For patients with creatinine clearance of 30 ～ 60 mL/min, a reduced dose of 30 mg once daily is recommended. For patients with creatinine clearance of 10 ～ 30 mL/min, a reduced dose of 30 mg every other day is recommended. Patients receiving regular hemodialysis should receive a 30 mg dose of this medicine after every 2 dialysis sessions to maintain blood concentrations within the therapeutic range. The first dose may also be administered before the start of dialysis. For peritoneal dialysis, 30 mg of this medicine after dialysis once weekly is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min), so no recommended dose is available for these patients. Patients with hepatic impairment: No dose adjustment is required for prevention in adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9).

Children's dosage

Children 1 to 12 years of age: Pediatric patients weighing more than 40 kg who are able to swallow capsules may take 75mg capsules twice daily or 30mg and 45mg capsules twice daily instead of the recommended dose of this medicine as a suspension. ≤ 15 kg: 30 mg twice daily; suspension (6mg/mL), 5.0 mL twice daily 15 kg<, ≤ 23 kg: 45 mg twice daily; suspension (6mg/mL), 7.5 mL twice daily 23 kg<, ≤ 40 kg: 60 mg twice daily; suspension (6mg/mL), 10.0 mL twice daily > 40 kg: 75 mg twice daily; suspension (6mg/mL), 12.5 mL twice daily Children 2 weeks to under 1 year of age: The recommended dose for pediatric patients 2 weeks to 12 months of age is 3mg/kg of this medicine orally twice daily for 5 days. This does not apply to children with a post-conceptional age of less than 36 weeks. 3 kg: 9 mg twice daily; suspension (6mg/mL), 1.5 mL twice daily 4 kg: 12 mg twice daily; suspension (6mg/mL), 2.0 mL twice daily 5 kg: 15 mg twice daily; suspension (6mg/mL), 2.5 mL twice daily 6 kg: 18 mg twice daily; suspension (6mg/mL), 3.0 mL twice daily 7 kg: 21 mg twice daily; suspension (6mg/mL), 3.5 mL twice daily 8 kg: 24 mg twice daily; suspension (6mg/mL), 4.0 mL twice daily 9 kg: 27 mg twice daily; suspension (6mg/mL), 4.5 mL twice daily 10 kg: 30 mg twice daily; suspension (6mg/mL), 5.0 mL twice daily * This table does not include all possible body weights for this patient group. A dose of 3mg/kg of this medicine is recommended for children under 1 year of age. It is recommended that a pharmacist prepare the suspension of this medicine before it is administered to the patient. Prevention of influenza A and influenza B virus infections Children 1 to 12 years of age: Pediatric patients weighing more than 40 kg who are able to swallow capsules may take 75mg capsules once daily or 30mg and 45mg capsules once daily for 10 days instead of the recommended dose of this medicine as a suspension. ≤ 15 kg: 30 mg once daily; suspension (6mg/mL), 5.0 mL once daily 15 kg<, ≤ 23 kg: 45 mg once daily; suspension (6mg/mL), 7.5 mL once daily 23 kg<, ≤ 40 kg: 60 mg once daily; suspension (6mg/mL), 10.0 mL once daily > 40 kg: 75 mg once daily; suspension (6mg/mL), 12.5 mL once daily It is recommended that a pharmacist prepare the suspension of this medicine before it is administered to the patient. ※ The safety and efficacy of this medicine for the prevention of influenza A and B virus infections in children under 1 year of age have not been evaluated.

This drug is used to treat or prevent influenza viruses but cannot replace influenza vaccination. This drug has only proven efficacy against Influenza A and B viruses, and its safety and efficacy against other infections have not been verified. Particularly in children and adolescents, neuropsychiatric adverse reactions such as seizures, delirium, and abnormal behavior have been reported, necessitating caution. If abnormal behavior occurs during treatment, it should be immediately observed by guardians and consulted with healthcare professionals if necessary. Individuals with allergies to this drug or its components should not take it, and patients with impaired kidney function may require dosage adjustment or avoidance of the drug. The most common side effects during treatment are nausea, vomiting, headache, etc., which are generally transient and mild symptoms. Rarely, serious allergic reactions, liver dysfunction, skin rash, CNS symptoms may occur, so if any unusual symptoms arise, treatment should be stopped immediately and a doctor should be notified. Pregnant or breastfeeding women should discuss thoroughly with a doctor before using this drug, and it should only be used when the therapeutic benefit outweighs the risk. This drug is not recommended for use in children under 1 year of age, as safety and efficacy have not been sufficiently studied. Elderly patients may also use it without special dosage adjustments but should be monitored carefully if there is a decline in body function or other illnesses. This drug has a low possibility of interactions with other medications; however, caution may be needed when used in conjunction with specific drugs, so patients must inform healthcare professionals if they are taking any other medications. It is important to start administration of this drug as soon as possible from the onset of influenza symptoms and to adhere to the dosing schedule. Keep this medication out of reach of children, and transferring it to another container should be avoided.

• Convulsions
• delirium
• abnormal behavior
• nausea
• vomiting
• headache
• pain
• unstable angina
• anemia
• pseudomembranous colitis

This medication should be stored in a tightly closed container to protect it from air and moisture, preferably at a cool temperature below 25 degrees Celsius. Storing it this way helps maintain the drug's effectiveness for a longer period.

Appearance

Gray hard capsule containing white or light yellow powder

Package unit

10 capsules/PTP